Kennedy Ferruggia, Assistant Editor

The findings further the understanding of respiratory virus immune evasion mechanisms and uncover how RSV-NS1 can target therapeutic intervention

"Risk Less. Do More." plans to partner with national, state, and local organizations to provide resources to families and communities on how to protect themselves from RSV, influenza, and COVID-19.

Mirdametinib is an oral, allosteric small molecule MEK inhibitor to treat pediatric patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN).

Eight areas of improvement were developed as part of national initiative with stakeholder involvement.

Pegcetacoplan is a targeted C3 therapy that is intended to regulate excessive activation of the complement cascade.

Pediatric patients weighing 20 kg to <50 kg should take 20 mg of apremilast twice daily and children weighing at least 50 kg should take 30 mg twice daily.

Building trust between techs and patients makes administering vaccines easier and increase immunizers’ confidence.

Pharmacists can help caregivers by recommending a healthy balanced diet containing high vitamin D intake and supplementation when needed.

Researchers assess the safety, tolerability, and immunogenicity of a single combination dose to evaluate its immunogenicity against SARS-CoV-2 and influenza.

Individuals with chronic conditions like asthma, diabetes, and chronic obstructive pulmonary disease face an increased risk of developing RSV.

The breakthrough therapy designation was granted based on ongoing data from the ARTEMIS-001 phase 1 open-label, multi-center trial.

Fam-trastuzumab deruxtecan-nxki has received 4 breakthrough therapy designations, including the latest approval.

Nurx reproductive access survey reveals 28% of women do not believe their right to contraception is protected.

RSV and influenza vaccines demonstrated hemagglutination inhibition titers that were noninferior to those with sequential administration.

The supplemental biologics license application was granted based on results from the ADRIATIC phase 3 trial among individuals with limited stage small cell lung cancer.

Individuals with Parkinson disease reported a decrease in bacterial genes for biosynthesis of riboflavin (vitamin B2) and biotin (vitamin B7).

The commencement of the phase 1 clinical trial of SAT-3247 is expected in Q3 of 2024.

The study is expected to include 460 individuals that will be randomly treated with 12mg of ifinatamab deruxtecan or chemotherapy chosen by the health care provider.

The primary end point of clinical remission at week 26 was met, with 36.7% of individuals treated with RHB-104 achieving clinical remission.

Following a healthy, vitamin rich diet with less sugar was connected to a lower epigenetic age.

The mRNA-1345 vaccine provides a one-off mechanism of protection because of its single-dose prefilled syringes

Dolutegravir/lamivudine was non-inferior to bictegravir/emtricitabine/tenofovir alafenamide fumarate, meeting the study’s primary end point.

One-third of patients treated with deuruxolitinib displayed 80% of scalp hair coverage.

Individuals who consumed 100 grams of carrots displayed an increase in carotenoid scores by 10.8%.

Pharmacologic approaches can increase the use of injectables.

The Lancet published data from DELTA 1 and DELTA 2 trials that displayed treatment success among individuals treated with delgocitinib cream.

AIC100 could meet an unmet medical need to effectively treat individuals with anaplastic thyroid cancer — the most aggressive form of the disease.

Vitamin C can improve levels of Nonheme Ferrous Fumarate or Ferrous Sulfate in the body

Individuals that followed the Mediterranean diet with EPA-DHA supplements displayed an increase in omega-3 levels which improved clinical appearance.